STOCK TITAN

Ligand Pharms CVR (LGNDZ) Revenue by Year

LGNDZ OTC

Ligand Pharms Inc CVR generated $268.1M in revenue in fiscal year 2025. This represents an increase of 60.4% from the prior fiscal year. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to $253.8M in revenue. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Ligand Pharms Inc CVR has filed alongside them.

FY2025 annual
Revenue $268.1M
YoY +60.4%
5Y CAGR +10.4%
10Y CAGR +14.1%
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

LGNDZ Revenue by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1410-KFY1310-KFY1210-KFY1110-K
Revenue$253.8M$268.1M+60.4%$167.1M+27.3%$131.3M-33.1%$196.2M-18.8%$241.5M+47.7%$163.6M+36.0%$120.3M-52.2%$251.5M+78.2%$141.1M+29.5%$109.0M+51.5%$71.9M+11.4%$64.5M+31.8%$49.0M+56.0%$31.4M+4.5%$30.0M

TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

LGNDZ Revenue by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-K
Revenue$78.7M-31.8%$63.7M+33.7%$51.7M+14.1%$59.7M+39.4%$115.5M+122.8%$47.6M+14.7%$45.3M+46.3%$42.8M+52.4%$51.8M+57.6%$41.5M+57.5%$31.0M-29.6%$28.1M-44.2%

What revenue means

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.

More Ligand Pharms Inc CVR financials

Frequently Asked Questions

Ligand Pharms Inc CVR generated $268.1M in revenue in fiscal year 2025.

Ligand Pharms Inc CVR (LGNDZ) revenue rose by 60.4% year over year, from $167.1M to $268.1M in fiscal year 2025.

Ligand Pharms Inc CVR (LGNDZ) reported $253.8M in revenue over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

Across the 15 fiscal years this page covers, Ligand Pharms Inc CVR (LGNDZ) revenue went from $30.0M in fiscal year 2011 to $268.1M in fiscal year 2025.

Ligand Pharms Inc CVR (LGNDZ) reported $78.7M in revenue in Q3 2026. This represents a decrease of 31.8% from the same quarter a year earlier.

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what Ligand Pharms Inc CVR (LGNDZ) reported on that line in every period on record.